The Administration/Communication Core (Core A) is proposed to facilitate coordination and oversight of all Program activities. This core will include a basic science director (Dr. T.-C. Wu) and a clinical research director (Dr. Edward Partridge). Dr. Wu will be responsible for coordinating basic scientific efforts and the coordination of individual projects. Dr. Partridge will oversee patient identification, enrollment, and patient monitoring in the context of the Core. This resource will also fund a Clinical Research Coordinator who will interact with the Biostatistics/Data Management Core (Core B), the Tissue/Pathology Core (Core C) and the Immunology Core (Core D), as well as with personnel from each individual project to ensure that all patient information, specimens, and results are properly collected and recorded in the computerized database. Appropriate monitoring of patient safety, adverse events, and data management and confidentiality will be provided by the data safety monitoring board, as well as the Clinical Research IVlanagement Group. The Administrative Core includes key administrative personnel and will also coordinate essential Program interactions including preparing applications and progress reports for the SPORE, all planning and evaluation activities, arranging and publicizing SPORE activities, coordinating advisory committee meetings, producing annual reports and performing analysis of budgetary matters.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-M)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Johns Hopkins University
United States
Zip Code
Yang, Andrew; Farmer, Emily; Lin, John et al. (2016) The current state of therapeutic and T cell-based vaccines against human papillomaviruses. Virus Res :
Yang, Andrew; Farmer, Emily; Wu, T C et al. (2016) Perspectives for therapeutic HPV vaccine development. J Biomed Sci 23:75
Khan, Michelle J; Massad, L Stewart; Kinney, Walter et al. (2016) A common clinical dilemma: Management of abnormal vaginal cytology and human papillomavirus test results. Gynecol Oncol 141:364-70
Khan, Michelle J; Massad, L Stewart; Kinney, Walter et al. (2016) A Common Clinical Dilemma: Management of Abnormal Vaginal Cytology and Human Papillomavirus Test Results. J Low Genit Tract Dis 20:119-25
Jiang, Rosie T; Schellenbacher, Christina; Chackerian, Bryce et al. (2016) Progress and prospects for L2-based human papillomavirus vaccines. Expert Rev Vaccines 15:853-62
Wang, Yi-Shu; Chen, Jianfeng; Cui, Fengmei et al. (2016) LKB1 is a DNA damage response protein that regulates cellular sensitivity to PARP inhibitors. Oncotarget :
Sun, Yun-Yan; Peng, Shiwen; Han, Liping et al. (2016) Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cell-Mediated Tumor Control in the Genital Tract. Clin Cancer Res 22:657-69
Jones, Jacqueline; Mukherjee, Angana; Karanam, Balasubramanyam et al. (2016) African Americans with pancreatic ductal adenocarcinoma exhibit gender differences in Kaiso expression. Cancer Lett 380:513-22
Randles, Leah; Anchoori, Ravi K; Roden, Richard B S et al. (2016) The Proteasome Ubiquitin Receptor hRpn13 and Its Interacting Deubiquitinating Enzyme Uch37 Are Required for Proper Cell Cycle Progression. J Biol Chem 291:8773-83
Yang, Andrew; Jeang, Jessica; Cheng, Kevin et al. (2016) Current state in the development of candidate therapeutic HPV vaccines. Expert Rev Vaccines 15:989-1007

Showing the most recent 10 out of 251 publications